New therapeutic approaches to cystic fibrosis;Article original récentes approches thérapeutiques de la mucoviscidose

Annales Pharmaceutiques Francaises

Volumn 61, Issue 4, 2003, Pages 253-258

  Willemot, J M ^a,b   Gaudelus, I Sermet ^a   Lenoir, G ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Hopital Necker Enfants Malades ^*  (France)

Author keywords

CFTR protein; Colchicin; Cystic fibrosis

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; DORNASE ALFA; GENISTEIN; GENTAMICIN; MULTIDRUG RESISTANCE PROTEIN; TRETOQUINOL; CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; CYSTIC FIBROSIS; DISEASE COURSE; GENE THERAPY; GENOTYPE; GRAM NEGATIVE INFECTION; HUMAN; PHENOTYPE; STOP CODON; SURGICAL DRAINAGE; GENETICS; REVIEW;

COLCHICINE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENOTYPE; HUMANS; PHENOTYPE;

EID: 0038038278     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rault G, Guilloud-Bataille M, Feingold J. Mucoviscidose: analyse comparative des données épidémiologiques dans les observatoires français et nord-américains. Rev Pneum Clin 1995; 51: 115-21.
2. Bear CE, Li C, Kartner N, Bridges RJ, Jensen TJ, Ramjeesingh M et al. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator. Cell 1992; 68: 809-18.
3. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Bio 1992; 8: 67-113.
4. Anderson MP, Gregory RJ, Thompson S, Souza DW and col. Demonstration that CFTR is a chloride Channel by alteration of its anion selectivity. Science 1991; 253: 202-5.
5. Wine JJ. The genesis of cystic fibrosis lung disease. J Clin Invest 1999; 103 (3): 309-12.
6. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human b-defensine-1 in a salt sensitiveantibioticin lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-60.
7. Jaffé A, Bush A, Geddes DM, Alton EWFW. Prospects for gene therapy in cystic fibrosis. Arch Dis Child 1999; 80: 286-9.
8. Laboratoires Roche: bibliographie
9. Pons G, Marchand MC, Foucard C, Chaumet-Riffaud P, d'Athis P, Lenoir G, et col. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 1995; Suppl 12: 193
10. Lazarowski ER, Watt WC, Stutts MJ, Brown HA, Boucher RC, Harden TK. Enzymatic synthesis of UTP gammas, a potent hydrolysis resistant agonist of P2U receptors. Br J Pharmacol 1996; 117: 203-9
11. Wilschanski M, Virgilis D, Stauss-Liviatan et col. Gentamicin causes functional expression of CFTR in CF patients carrying stop mutation: a double blind placebo controles trial. Pediatr Pulmonol 2000; suppl 20.
12. Howard M, Frizzell R, Bedwell D. Aminoglycodide antibiotics restore CFTR function by over coming premature stop mutations. Nature Med 1997; 3: 1280-4.
13. Yang IC, Cheng TH, Wang F, Price EM, Hwang TC. Modulation of CFTR chloride channels by calyculin A and genistein. Am J Physiol 1999; 272: C 142 C 155.
14. Winnie GB, Devor DC, Tatlor NR et al. Genistein stimulates chloride secretion in normal volunteers but not in CF patients homozygotes for the delta F 508 mutation. Pediatr Pulmonol 2000; suppl 20.
15. Lallemand J, Stoven V, Annereau J P, Boucher J, Blanquet S, Barthe J et al. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350: 711-2
16. Annereau J P, Stoven V, Bontems F, et al. Insight into cystic fibrosis by structural modelling of CFTR first nucleotide binding fold (NBF1). C. R Acad. Sci. Paris Sciences de la vie/Life Science 1997; 320: 113-21.
17. Trezise AE, Racliff R, Hawkins TE, et al. Coordinate regulation of the cystic fibrosis and multidrug resistance genes in cystic fibrosis knockout mice. Hum Mol Genet 1997; 6: 527-37
18. Hollo Z, Homoyala T, Hegedus T, Sarkadi B. Transport properties of the multidrug resistance associated protein (MRP) in human tumor cells; FEBS Lett 1996; 383: 99-104
19. Raymond M, Gros P, Whiteway M, Thomas DY. Functionnal complementation of yeast by a mammalian mutidru resistance mdr gene. Science 1996; 256: 232-41992
20. Altschuler EL. Azithromycin, the multidrug resistance protein and cystic fibrosis. Lancet 1998; 351: 1286
21. Lenoir G, Sermet I, Sorin M, Duhamel JF, Chretiennot C, Guillerm JC et al. Interest of colchicin in cystic fibrosis patients. XIIIth International Cystic Fibrosis Congress Stockholm 2000, abstract 102: 115.